Similarly, the hypothetical advantage of displaying cell membrane phospholipid synthesis as an index of cell growth (with radio-labelled choline) or targeting the expression of Prostate-Specific Membrane Antigen (PSMA) on PCa tumour cells through PET/CT still needs to be verified in this clinical setting. The gene discussed is FOLH1; the disease is neoplasm.